These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27058224)

  • 21. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis.
    Yeh EA; Weinstock-Guttman B; Ramanathan M; Ramasamy DP; Willis L; Cox JL; Zivadinov R
    Brain; 2009 Dec; 132(Pt 12):3392-400. PubMed ID: 19892770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI outcomes in the diagnosis and disease course of multiple sclerosis.
    Simon JH
    Handb Clin Neurol; 2014; 122():405-25. PubMed ID: 24507528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
    Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
    J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Magnetic resonance in the diagnosis and treatment of multiple sclerosis].
    Rovira Cañellas A
    Neurologia; 2000; 15(7):288-302. PubMed ID: 11075577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurophysiological investigations in multiple sclerosis.
    Leocani L; Comi G
    Curr Opin Neurol; 2000 Jun; 13(3):255-61. PubMed ID: 10871248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MRI visualization of multiple sclerosis lesions].
    Berry I; Ranjeva JP; Manelfe C; Clanet M
    Rev Neurol (Paris); 1998 Sep; 154(8-9):607-17. PubMed ID: 9809376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
    Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
    Sepulcre J; Goñi J; Masdeu JC; Bejarano B; Vélez de Mendizábal N; Toledo JB; Villoslada P
    Arch Neurol; 2009 Feb; 66(2):173-9. PubMed ID: 19204153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years.
    Schlaeger R; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
    Mult Scler; 2014 Sep; 20(10):1348-54. PubMed ID: 24574192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using MRI to make informed clinical decisions in multiple sclerosis care.
    Bermel RA; Naismith RT
    Curr Opin Neurol; 2015 Jun; 28(3):244-9. PubMed ID: 25887772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of MRI in measuring the effectivity of disease modifying treatments II].
    Kincses Z; Tóth E; Fricska-Nagy Z; Füvesi J; Rajda C; Bencsik K; Vörös E; Csomor A; Palkó A; Vécsei L
    Ideggyogy Sz; 2018 Mar; 71(3-04):81-88. PubMed ID: 29889466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel MRI and PET markers of neuroinflammation in multiple sclerosis.
    Hagens M; van Berckel B; Barkhof F
    Curr Opin Neurol; 2016 Jun; 29(3):229-36. PubMed ID: 27058220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of brainstem involvement in multiple sclerosis.
    Habek M
    Expert Rev Neurother; 2013 Mar; 13(3):299-311. PubMed ID: 23448219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of long-term disability in multiple sclerosis.
    Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
    Mult Scler; 2012 Jan; 18(1):31-8. PubMed ID: 21868486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis.
    Amato MP; Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; De Stefano N
    Neurology; 2008 Aug; 71(9):632-8. PubMed ID: 18725589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis in children: clinical, neuroimaging, and neurophysiological correlations.
    Wang PJ; Tseng CL; Young C; Liu HM; Chang YC; Shen YZ; Lee CY
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1995; 36(2):93-100. PubMed ID: 7793286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis.
    Sbardella E; Tomassini V; Stromillo ML; Filippini N; Battaglini M; Ruggieri S; Ausili Cefaro L; Raz E; Gasperini C; Sormani MP; Pantano P; Pozzilli C; De Stefano N
    Mult Scler; 2011 Dec; 17(12):1432-40. PubMed ID: 21729978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
    Barkhof F; van Walderveen M
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1675-86. PubMed ID: 10603619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.
    Sormani MP; Pardini M
    Neurotherapeutics; 2017 Oct; 14(4):924-933. PubMed ID: 28695472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.